Brian Badgwell, MD, MS

Professor of Surgery
MD Anderson Cancer Center
Houston, Texas, United States

Dr. Badgwell has a cancer-directed practice in gastric and gastroesophageal cancer at MD Anderson that incorporates recent progress in advanced minimally invasive surgery and intraperitoneal chemotherapy. He was the principal investigator for the first three completed trials of HIPEC for gastric cancer in the United States, and performed all surgeries for the patients on these trials. He has established a palliative surgery research program dedicated to improving the quality of life for patients with symptoms due to advanced cancer and, with funding through the American Cancer Society, has developed the first validated symptom assessment questionnaire for patients with malignant bowel obstruction

Presentation(s):

• 71: Phase I Trial of Intraperitoneal Paclitaxel in Patients with Gastric Adenocarcinoma and Peritoneal Carcinomatosis or Positive Peritoneal Cytology

  Thursday, March 21, 2024
  2:22pm – 2:32pm ET

• 89: Survival Outcomes in Patients with Resectable Gastric Cancer Treated with Total Neoadjuvant Therapy

  Friday, March 22, 2024
  10:32am – 10:42am ET

• 92: Phase I Trial of Short-Course Chemoradiotherapy followed by Chemotherapy as Total Neoadjuvant Therapy for Patients with Potentially Resectable Gastric Cancer

  Friday, March 22, 2024
  11:02am – 11:12am ET